Canadian News

Tuesday, December 28, 2021

Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

Thursday, June 17, 2021

Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinson’s disease.

Wednesday, April 7, 2021

Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business

Monday, January 25, 2021

Servier obtains Top Employer Europe 2021 certification

Wednesday, January 20, 2021

Servier Group – Financial Year 2019/2020

Financial results and R&D strategy and pipeline

Monday, December 14, 2020

The Servier Group opens a worldwide Artificial Intelligence Hub in Montreal, in partnership with Centech

Monday, August 31, 2020

New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and intracranial hemorrhage (ICH) rates in frail and elderly AF patients on LIXIANA® (edoxaban) during routine clinical care

Thursday, June 4, 2020

Servier completes the acquisition of Symphogen


Thursday, April 2, 2020

Servier partners with Innovative Medicines Canada Members to Donate 100,000 Masks to Help Protect Front-Line Healthcare Workers Battling COVID-19

Wednesday, April 1, 2020

Coronavirus Information (COVID-19)

Thursday, March 5, 2020

Servier Group – Financial Year 2018/19 : Financial results and R&D pipeline

Wednesday, September 4, 2019

ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NonValvular Atrial Fibrillation Patients

Tuesday, September 3, 2019

Servier Canada announces Positive Results of the ENTRUSTAF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation

Wednesday, March 13, 2019

LIXIANA® (edoxaban) now reimbursed by the Régie de l’assurance maladie du Québec for patients with atrial fibrillation or venous thromboembolism

Monday, November 5, 2018

LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure

Thursday, November 1, 2018

Servier Receives Health Canada Approval of FOLOTYN® for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Thursday, September 27, 2018

LANCORA™ (ivabradine) now covered by the Régie de l’assurance maladie du Quebec for patients suffering from heart failure

Tuesday, September 11, 2018

Servier Canada Announces the Availability of ZEVALIN®, the Only Single-course Chemo-free Treatment Regimen for the Treatment of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma.

Wednesday, September 5, 2018

Servier Canada announces the Expansion of its Oncology Portfolio through the acquisition by Servier group of Shire’s oncology branch

Tuesday, June 19, 2018

Servier Canada, in collaboration with Hypertension Canada, launches the GETDOWNBP Hypertension Management mobile App

Monday, January 15, 2018

Servier Canada and the New Brunswick Health Research Foundation announce the creation of the Servier-New Brunswick Cardiac Health Improvement Fund (CHIF)

Wednesday, January 10, 2018

Servier and Treventis begin strategic research partnership in neurodegenerative diseases

Friday, December 15, 2017

Once-Daily Oral Anticoagulant LIXIANA(edoxaban) met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Thursday, November 23, 2017

Servier Canada establishes a new partnership with CQDM to fund a diabetes research project.

Friday, November 10, 2017

Servier Canada announces the launch of VENIXXA, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids.

Tuesday, June 20, 2017

Servier Canada, Government of Alberta, and the University Hospital Foundation announce the formation of the Servier Alberta Innovation in Health Fund (SAIHF)

Wednesday, May 3, 2017
ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation was initiated
Monday, April 3, 2017
SERVIER CANADA Announces New Toronto Offices
Friday, March 31, 2017
ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation was initiated.
Tuesday, February 7, 2017

Servier announces an increase in turnover for 2015-2016. Growth bolstered by strong international performance

Tuesday, January 10, 2017

Health Canada approves new heart failure treatment LANCORA to reduce mortality and hospitalizations

Wednesday, December 7, 2016

GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis 

Wednesday, November 9, 2016

Once-Daily Anticoagulant LIXIANA® (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism

Thursday, October 20, 2016

New compound shows promise in treating multiple human cancers

Monday, September 26, 2016

$21 Million Investment in Québec Biotech Start-up to Develop a Treatment for Venous Lower Limb Ulcers

Thursday, September 1, 2016

Amgen and Servier extend omecamtiv mecarbil collaboration in chronic heart failure 

Monday, June 27, 2016

Servier Canada is pleased to announce the signing of a strategic agreement with Daiichi Sankyo Co., Limited

Friday, January 29, 2016

Viacoram now approved in Canada as a new first line treatment in hypertension

Tuesday, January 12, 2016

Spectrum Pharmaceuticals signs a strategic partnership with Servier Canada

Thursday, November 19, 2015

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19

Thursday, November 13, 2014
INTARCIA and SERVIER sign EX-U.S. partnership for ITCA 650 in diabetes
Friday, October 10, 2014
Friday, September 19, 2014
SERVIER and CTI BIOPHARMA announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI
Friday, April 18, 2014
Servier Research Group announces the death of President-Founder Dr. Jacques Servier
Wednesday, April 16, 2014
Servier: one of France’s most remarkable industrial undertakings
Friday, February 14, 2014
Servier Canada invests $10M in two research projects supported by the Partnership Fund for an Innovative, Healthy Quebec